Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells. Issue 2 (14th July 2020)

• Record Type: Journal Article
• Authors: Hu, Fangxiao; Huang, Dehao; Luo, Yuxuan; Zhou, Peiqing; Lv, Cui; Wang, Kaitao; Weng, Qitong; Liu, Xiaofei; Guan, Yuxian; Geng, Yang; Du, Juan; Chen, Jiekai; Wang, Jinyong; Wu, Hongling
• Is Part Of: Journal for immunotherapy of cancer. Volume 8:Issue 2(2020)
• Publication Date: 2020-07-14
• Subjects: T lymphocytes -- melanoma -- immunotherapy; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2019-000498
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Tumor-associated antigen (TAA) T-cell receptor (TCR) gene-engineered T cells exhibit great potential in antitumor immunotherapy. Considering the high costs and low availability of patient-derived peripheral blood T cells, substantial efforts have been made to explore alternatives to natural T cells. We previously reported that enforced expression of Hoxb5 converted B cells into induced T (iT) cells in vivo . Here, we successfully regenerated naive OT1 (major histocompatibility complex I restricted ovalbumin antigen) iT cells (OT1-iT) in vivo by expressing Hoxb5 in pro-pre-B cells in the OT1 transgenic mouse. The OT1-iT cells can be activated and expanded in vitro in the presence of tumor cells. Particularly, these regenerated OT1-iT cells effectively eradicated tumor cells expressing the TAA (ovalbumin) both in vitro and in vivo . This study provides insights into the translational applications of blood lineage-transdifferentiated T cells in immunotherapy.